Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early upacicalcet intervention for coronary artery calcification in dialysis patients with secondary hyperparathyroidism
jRCTs041220126Active, not recruiting
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of upacicalcet in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoint: Change in log-transformed CACS volume at 52 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on jRCTs041220126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220126.